US20130052648A1 - Amplifying rare cell surface markers - Google Patents
Amplifying rare cell surface markers Download PDFInfo
- Publication number
- US20130052648A1 US20130052648A1 US13/583,478 US201113583478A US2013052648A1 US 20130052648 A1 US20130052648 A1 US 20130052648A1 US 201113583478 A US201113583478 A US 201113583478A US 2013052648 A1 US2013052648 A1 US 2013052648A1
- Authority
- US
- United States
- Prior art keywords
- cells
- cell
- peptide
- protein
- subsamples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 170
- 238000000034 method Methods 0.000 claims description 54
- 230000003321 amplification Effects 0.000 claims description 27
- 238000001514 detection method Methods 0.000 claims description 27
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 230000028327 secretion Effects 0.000 claims description 21
- 239000012530 fluid Substances 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 16
- 238000005096 rolling process Methods 0.000 claims description 15
- 230000007246 mechanism Effects 0.000 claims description 13
- 238000005259 measurement Methods 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 4
- -1 e.g. Substances 0.000 claims description 4
- 108020004638 Circular DNA Proteins 0.000 claims description 2
- 239000012051 hydrophobic carrier Substances 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 abstract description 13
- 238000005538 encapsulation Methods 0.000 abstract description 12
- 238000011534 incubation Methods 0.000 abstract description 11
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 15
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 239000004005 microsphere Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000002458 cell surface marker Substances 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 210000005266 circulating tumour cell Anatomy 0.000 description 2
- 108010047295 complement receptors Proteins 0.000 description 2
- 102000006834 complement receptors Human genes 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000031261 interleukin-10 production Effects 0.000 description 2
- 238000002032 lab-on-a-chip Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002120 photoresistant polymer Polymers 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- NGDLSKPZMOTRTR-OAPYJULQSA-N (4z)-4-heptadecylidene-3-hexadecyloxetan-2-one Chemical compound CCCCCCCCCCCCCCCC\C=C1/OC(=O)C1CCCCCCCCCCCCCCCC NGDLSKPZMOTRTR-OAPYJULQSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000006270 Proton Pumps Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004175 meibomian gland Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000000678 plasma activation Methods 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002174 soft lithography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1484—Electro-optical investigation, e.g. flow cytometers microstructural devices
-
- G01N15/01—
-
- G01N15/149—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/10—Oligonucleotides as tagging agents for labelling antibodies
Definitions
- the invention relates to systems and methods for detecting molecules secreted from a single cell and rare cell surface markers, in particular, systems and methods using rolling circle amplification with microfluidic devices for encapsulation, incubation, and analysis of cell surface markers or secreted molecules from a single cell.
- ELISA enzyme-linked immunosorbent assay
- the present invention is based, at least in part, on systems and methods for amplifying rare cell surface markers, in particular, systems and method using rolling circle amplification with microfluidic devices for encapsulation, incubation, and analysis of cell surface markers or secreted molecules from a single cell.
- the methods and systems described below can provide high efficiency techniques for specific detection and amplification of cell specific surface markers.
- the identification of cell surface antigens can be critical to the development of new diagnostic and therapeutic modalities for the management of diseases such as, for example, cancer.
- RCA rolling circle amplification technique
- RCA is a simple amplification method with high sensitivity and specificity owing to the DNA stringent strand matching requirement and its high signal amplification efficiency (see e.g., Konry et al., Analytical Chemistry 81(14), 5777-5782 (2009); Demidov, Expert Rev. Mol. Diagn., 2(6), 89-95, (2002); and Landegren et al., Comp. Funct. Genomics, 4, 525-530, (2003)).
- RCA technology detects and measures proteins as well as nucleic acids with unprecedented sensitivity and expanded multiplexing capabilities.
- a cell specific surface marker is a molecule usually found on the plasma membrane of a specific cell type or limited number of cell types. These markers can be extremely useful to distinguish diseased cells or tissues from those in normal state.
- the presented technique can be applied to identify, detect, and quantify specific types of cells in complex multi-cellular systems fixed on a glass slide, biochip platform or in flow cytometry analysis.
- methods of for detecting cell-surface expression or secretion of a protein or peptide by a single cell include: providing a sample comprising a population of cells and reagents sufficient for detection of a protein or peptide; dividing the sample into subsamples, such that each subsample contains at most one of the population of cells and each subsample is encompassed a hydrophobic fluid; maintaining the subsamples under conditions sufficient to allow detection of the protein or peptide; and detecting the protein or peptide; thereby detecting expression of the protein or peptide by a single cell.
- Embodiments can include one or more of the following features.
- the protein or peptide is expressed on the surface of the cell or secreted from the cell.
- the reagents comprises rolling circle amplification reagents, e.g., phi29 DNA polymerase, and circular DNA template.
- the reagents comprise antibodies, e.g., antibodies that bind specifically to the protein or peptide.
- the method further comprises sorting the cells based on expression of the protein or peptide. In some cases, wherein sorting the cells comprises using a Fluorescence Activated Cell Sorter (FACS).
- FACS Fluorescence Activated Cell Sorter
- dividing the sample into subsamples comprises combining fluids from multiple inlet channels.
- combining the fluids from multiple inlet channels comprises combining aqueous sample fluid from a first inlet channel with a hydrophobic carrier fluid, e.g., oil, from at least one second inlet channel.
- systems for detecting expression of a specific protein or peptide by individual cells of a population of cells include: a fluid control device configured to divide a sample comprising the population of cells into subsamples, such that each subsample contains at most one of the population of cells and each subsample is encompassed a hydrophobic fluid; rolling circle amplification reagents for detection of the presence of the specific protein or peptide; and a device operable to detect the rolling circle amplification reagents in individual subsamples.
- a fluid control device configured to divide a sample comprising the population of cells into subsamples, such that each subsample contains at most one of the population of cells and each subsample is encompassed a hydrophobic fluid
- rolling circle amplification reagents for detection of the presence of the specific protein or peptide
- a device operable to detect the rolling circle amplification reagents in individual subsamples can include one or more of the following features.
- systems also include a cell sorting mechanism operable to sort the subsamples based on measurement of an indicator parameter in each subsample.
- the cell sorting mechanism comprises a fluorescence activated cell sorting mechanism.
- a kit in one aspect, includes: a fluid control device configured to divide a sample comprising the population of cells into subsamples, such that each subsample contains at most one of the population of cells and each subsample is encompassed a hydrophobic fluid; and rolling circle amplification reagents for detection of the presence of the specific protein or peptide.
- a fluid control device configured to divide a sample comprising the population of cells into subsamples, such that each subsample contains at most one of the population of cells and each subsample is encompassed a hydrophobic fluid
- rolling circle amplification reagents for detection of the presence of the specific protein or peptide.
- kits also include a device operable to detect the rolling circle amplification reagents in individual subsamples.
- kits also include a cell sorting mechanism operable to sort the subsamples based on measurement of an indicator parameter in each subsample.
- the cell sorting mechanism can include a fluorescence activated cell sorting mechanism.
- a microfluidic system was used to encapsulate single cells in monodisperse pico-liter RCA reaction droplets. Inclusion of fluorescent probes in the RCA reaction mix permitted the amplification process to be monitored within individual droplets. The resulting fluorescent signal can be the basis for microfluidic cell sorting based on a cell surface marker.
- a PDMS microfluidic device was used for the production of monodisperse aqueous emulsion droplets with each droplet containing at most a single cell with a RCA reaction mix.
- This microfluidic system for RCA offers the advantage of a reduction of reaction volumes, and thereby decreases in reagent and sample consumption which can be critical when limited analyte material is available from clinical samples. Since RCA is an isothermal reaction there is no need for thermal cycling that require sophisticated and expensive instrumentation if compared to microfluidic systems for PCR (see e.g., Konry et al., Analytical Chemistry 81(14), 5777-5782 (2009); Demidov, Expert Rev. Mol.
- the new technique will potentially, due to the large multiplexing capacity of RCA, the methods described herein enable parallel detection of various markers thus providing a highly multiplex method by using different combinations of spectrally resolvable fluorophores.
- Such versatility is superior over PCR-based approaches, since multiplex PCR needs optimization for each primer pair used and still has problems with uniformity.
- EpCAM EpCAM
- EpCAM Epidermal Cell Adhesion Molecule
- CTC circulating tumor cell
- anti-EpCAM antibody is used to identify the CTCs.
- Cells that express this specific cancer marker can serve as molecular targets for sensitive and specific detection.
- the described systems and methods can provide the ability to detect differential expression of EpCAM on the cancer cell using RCA signal that can reduce the likelihood that any target cells are missed.
- the PDMS microfluidic devices can be used for production of monodisperse aqueous emulsion droplets of picoliter or nanoliter in size in a continuous oil phase to encapsulate each cell in their own microenvironment.
- the size of a liquid jet can be considerably reduced to achieve faster mixing time. Since the volume of each drop is restricted, molecules secreted by an individual cell can rapidly attain detectable concentrations.
- Each droplet contains up to one individual cell encapsulated along with detection reagents, such as fluorescently labeled detection antibodies and conjugated microshperes for secreted analyte measurement (depending on the number of cells, some droplets may have no cells, but optimally no droplets will have more than one cell).
- secreted analytes bind to microspheres previously conjugated with analyte-specific antibodies and this binding is detected in real time via detection of a fluorescent signal from labeled antibodies also present in the droplets.
- the fluorescence diffuses in the droplet and is not localized on the microshpere surface. Because the cells in the droplets remain viable after encapsulation, the cells can be captured based on signals detected, and cultured to produce clonal populations of cells, e.g., using known cell-sorting and culture methods. It is also possible that the same set of droplets could be used overtime to produce multiple copies of single cell droplets-array at different time points.
- This method has an advantage in the fabrication process and device handling, which avoids washing and surface modification steps as compared to previously published single cell secretion analysis.
- other methods for the analysis of individual cells in large numbers do not allow both high-throughput analysis of a secreted product and recovery of living cells for clonal expansion.
- FIG. 1 is a schematic illustration of an RCA assay for the detection of a target surface protein.
- FIG. 2 is a schematic illustration of a microfluidic cell sorting system for RCA in drops.
- FIGS. 3A to 3D are a series of microscope images of PC3 cells fixed on a glass slide.
- FIG. 4 is a schematic illustration of experimental setup.
- FIGS. 5A to 5C are a series of microscope images of microfluidic devices for encapsulation in created droplets.
- FIG. 5D is a photograph of an incubation and analysis channel.
- FIGS. 6A and 6B are a series of (A) bright field and (B) fluorescence microscope images of aqueous droplets containing T cells, beads, and fluorescent secondary antibody.
- the systems and methods described herein are based, at least in part, on the discovery of methods for detecting molecules secreted by single cells and rare cell surface markers.
- the methods use rolling circle amplification with microfluidic devices for encapsulation, incubation, and analysis of cell surface markers or secreted molecules from a single cell. Detection of cell surface specific markers in microfluidic format can be utilized in a number of applications, e.g., in cancer cell diagnostics.
- a cell surface marker is a molecule found on the external cell wall or plasma membrane of a specific cell type or a limited number of cell types (see e.g., Molday and Maher, Histochemical Journal 12:273-315 (1980); Hewett, International Journal of Biochemistry & Cell Biology 33:325-335 (2001); and Pieriy et al., Applied and Environmental Microbiology 65:2877-2894 (1999)).
- FIG. 1 schematically illustrates an exemplary RCA assay for the detection of analytes, e.g., a target surface protein.
- anti-EPCAM antibody binds to a target EpCAM protein and is in turn bound by secondary biotin-labeled antibodies (step A).
- An avidin bridge captures a biotinylated DNA probe (step B). Cyclic DNA is hybridized to the primer (step C), and the capture probe is extended by polymerase (step D).
- any molecule that is secreted or found on the cell wall or plasma membrane of any cell e.g., a marker can be detected.
- cell surface markers that are expressed on a specific cell type or a limited number of cell types can be detected. The process will be described for use with cancer cells, although it may be adapted for use with other cells, e.g., stem cells and immune cells.
- cell surface markers include, but are not limited to, membrane proteins such as receptors, transporters, ion channels, proton pumps, and G protein-coupled receptors; extracellular matrix molecules such as adhesion molecules (e.g., integrins, cadherins, selectins, or NCAMS); See, e.g., U.S. Pat. No. 7,556,928, which is incorporated herein by reference in its entirety.
- T-cell receptor TCR
- CD5 T-cell receptor
- CD2 E-receptor
- MHC Class II molecules which are important in antigen presentation
- T H cells can be further subdivided into T H1 and T H2 , which produce different cytokines and have distinct physiological roles.
- secretion is the process of releasing a molecule from a cell, and occurs in prokaryotes and eukaryotes.
- secretion is an important mechanism in bacterial functioning and operation in their natural surrounding environment for adaptation and survival.
- Eukaryotic cells have a highly evolved process of secretion, which may involve the classical endoplasmic reticulum (ER)-Golgi pathway.
- ER endoplasmic reticulum
- Many mammalian cell types have the ability to be secretory cells and thus have a well developed ER and Golgi apparatus to fulfill this function.
- Cells in humans that produce secretions include those in the gastrointestinal tract, which secretes digestive enzymes and gastric acid; the lung, which secretes surfactants; sebaceous glands, which secrete sebum to lubricate the skin and hair; the pancreas, which secretes insulin; and meibomian glands in the eyelid, which secrete sebum to lubricate and protect the eye. Further, cells of the immune system can secrete cytokines and proteins.
- Secretome analysis can be used e.g., to examine molecules secreted from specific cells, measure time-dependent variability of secretion, and identify unique types of cells that respond to activation with specific analyte secretion.
- the process will be described for use with IL-10, although it may be adapted for use with other secreted molecules, e.g., proteins, peptides, enzymes, cytokines, chemokines, hormones, toxins, and antimicrobial peptides.
- IL-10 secretion was measured from a CD4+CD25+ regulatory T cell clone.
- IL-10 is an anti-inflammatory cytokine with pleiotropic activities on B, T, and mast cells and is produced by a variety of cell types in response to activation (Pestka et al., Annu Rev Immunol. 22:929-79 (2004)). It has been reported that diminished IL-10 production is associated with autoimmunity (Astier and Hafler, J. Neuroimmunol. 191:70-8 (2007)).
- IL-10 can exert its inhibitory activity through multiple effects on different cell types, it is important to understand how its secretion is regulated and to examine the unique cells that respond to IL-10. Understanding how IL-10 secretion is regulated in different cell types would be markedly enhanced by the ability to detect and re-isolate only those viable cells that are actively secreting IL-10 from the majority of cells in the population that are not producing IL-10.
- the technology described herein can be used to isolate IL-10 secreting cells by encapsulating cells, and later recovering the cells from the drops (e.g., using FACS).
- this method can also be applied to multitarget detection. Additional individually detectable microspheres that bind other targets can be incorporated in this type of secretion measurement. In this way, a single cell secretome can be achieved using multiple microspheres previously encoded with different capturing antibodies.
- the ability to use combinations of analytes for signal generation should enables simplification of sorting and detection analysis. For example, since monitoring of CD4+CD25+ regulatory T cells shows promise in cancer immunotherapy, the system can be applied to study new paradigms for designing cytokine antagonists and cell-cell regulation.
- FIG. 2 is a schematic illustration of a microfluidic cell sorting system for RCA in drops.
- the microfluidic device produces monodisperse aqueous emulsion droplets containing single cells and an RCA reaction mix. The droplets can then be incubated (e.g., stored in an incubation region of the microfluidic device).
- EpCAM is a pan-epithelial differentiation antigen that is expressed on almost all carcinomas, therefore detection of EpCAM-expressing cells in a sample can serve as first screening test for cancer (Spizzo et al., Breast Cancer Research and Treatment 86:207-213 (2004)).
- this specific tumor cell marker is usually used to identify a circulating tumor cell (CTC) (Nagrath et al., Nature 450:1235-1238 (2007)).
- CTC circulating tumor cell
- tumor cells that express a low level of EpCAM may not be detected directly by anti-EpCAM antibodies due to low signal intensity (Deng et al., Breast Cancer Research 10:1-11 (2008)). Therefore the ability to detect differential expression of EpCAM on the cell using a RCA signal can ensure that no target cells are missed.
- An RCA signal can be confined locally if the amplification primer is immobilized onto a solid support (Konry et al., Analytical Chemistry 81: 5777-5782 (2009); Smolina et al., Applied and Environmental Microbiology 73:2324-2328 (2007)) and the resulting signal can be detected directly via fluorescent microscopy and/or digitally quantified with a GenePix® microarray scanner (Smolina et al., Applied and Environmental Microbiology 73:2324-2328 (2007)). Two sets of experiments were performed. Representative results obtained in these experiments are presented in FIGS. 3A-3D .
- PC3 cells Fixed on a glass slide previously labeled with DAPI (blue) were taken.
- the PC3 cells were labeled directly with biotinylated anti-EpCAM antibodies and Cy3 fluorescent labeled streptavidin.
- the specificity of the system was also tested by applying the same conditions to lymphocytes. As lymphocyte cells do not express EpCAM, no fluorescent signal was detected using the direct detection method.
- PC3 cells were labeled using the RCA technique.
- the cells were first labeled with biotinylated anti-EpCAM antibodies.
- Biotinylated primers were immobilized via a biotin-avidin bridge to the biotinylated anti-EpCAM antibodies.
- circular template was immobilized to the primers and isothermally amplified by phi29 DNA polymerase.
- the RCA process preserves the integrity of antibody-antigen (EpCAM) complexes.
- the RCA product contains thousands of repeat sequences that contain fluorescently labeled nucleotides. RCA amplifies the detection signal and allows for the detection of PC3 cancer cells.
- Isothermal amplification using phi29 DNA polymerase was also performed in droplets.
- a drop-based PDMS microfluidic device was applied to encapsulate PC3 cells in distinct picoliter-sized drops of RCA reagents.
- a PDMS microfluidic system which generates monodisperse droplets in a microchannel through shearing flow at a T-junction or a flow-focusing zone has been previously described (Kiss et al., Anal. Chem. 80:8975-8981 (2008); Koster et al., Lab on a Chip, 8:1110-1115 (2008)).
- Other methods of generating droplets e.g., separating the sample into subsamples could also be used.
- the RCA reaction droplets were conveyed by the oil flow through channels in a microfluidic chip. Individual droplets were then focused in the array channel for amplification reaction of cell surface marker and optical interrogation ( FIGS. 3A to 3D ).
- An array like channel permits incubation for polymerization and measuring of fluorescence signal in real time from each individual cell, providing information on amplification efficiency within each droplet.
- the array channel herein permits simultaneous interrogation of multiple droplets/reactions/cells and it can be easily designed to hold thousands of droplets (Kiss et al., Anal. Chem. 80:8975-8981 (2008)). Comparing the fluorescent image of an encapsulated cell in an RCA reaction at the beginning of the incubation (see FIG.
- FIG. 4 illustrates a PDMS droplet-based microfluidic device.
- Three inlet channels form a nozzle as their flows combine (see FIGS. 5A and 5B ).
- the center stream contains beads, cell and secondary antibodies suspension while the side streams contain the oil phase.
- the size of the droplets controlled by matching the size of the nozzle orifice to the drop diameter and operating the device in the dripping regime.
- all drops should optimally contain at most one cell, so that the majority of drops contain no cell at all since the encapsulation process follows Poisson statistics. Although the number of single-cell-bearing drops is rather low, for these experiments this is not severe, given the high production and screening rate that can be achieved with microfluidic devices.
- Microfluidic flow chambers were fabricated by soft lithography. Negative photo resist SU-8 2025 or SU-8 2100 (MicroChem, Newton, Mass.) was deposited onto clean silicon wafers to a thickness of 50 lm, and patterned by exposure to UV light through a transparency photomask (CAD/Art Services, Bandon, Oreg.). The Sylgard 184 poly(dimethylsiloxane) (PDMS) (Dow Corning, Midland, Mich.) was mixed with crosslinker (ratio 10:1), poured onto the photoresist patterns, degassed thoroughly and cured for at least 1 hour at 65° C.
- PDMS poly(dimethylsiloxane)
- the PDMS devices were peeled off the wafer and bonded to glass slides after oxygen-plasma activation of both surfaces.
- the microfluidic channels are treated prior to the experiments with Aquapel (PPG Industries, Pittsburgh, Pa.) by filling the channels with the solution as received and then flushing them with air.
- Aquapel PPG Industries, Pittsburgh, Pa.
- Polyethylene tubing with an inner diameter of 0.38 mm and an outer diameter of 1.09 mm (Becton Dickinson, Franklin Lakes, N.J.) connected the channels to the syringes. Syringes were used to load the fluids into the devices, while the flow rates were controlled by syringe pumps.
- Optimum devices for drop formation and cell encapsulation are 40 lm high with a 35 lm-wide nozzle.
- a channel height of 25 lm and different nozzle widths.
- the channel for cell incubation are 100 lm high, the 1 width is 500 lm, and the length is 2.88 m. All inlet channels were equipped with patterned filters which prevent dust particles from clogging the channels downstream.
- CD4 T cells were isolated from human blood drawn from healthy control donors by Ficoll-Hypaque (Amersham Biosciences) gradient centrifugation, and total CD4 T cells were isolated by negative selection using a CD4+ T-cell isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) and stained for fluorescence-activated cell sorting (FACS) with antibodies against CD45RA (HI100), CD25 (M-A251), and HLA-DR (L-243).
- FACS fluorescence-activated cell sorting
- CD45RA ⁇ CD25med populations were sorted in a FACSAriaTM cell sorter (BD Biosciences) at one cell per well in XVIVO-15 (Lonza) medium containing 5% human serum and stimulated with soluble anti-CD3 (clone Hit3a, BD Biosciences) and anti-CD28 (clone 28.2) (both at 1 ⁇ g/mL), irradiated APCs (105/well), and IL-2 (50 U/mL). Half of the medium was replaced with fresh medium containing IL-2 (50 U/mL) starting at day 10 and every 3 to 4 days thereafter. After 4 weeks of expansion, each clone was tested for FoxP3 expression and IL-10 production.
- SPHEROTM Avidin Coated Particles (0.7-0.9 lm) were conjugated with biotinylated IL-10 monoclonal capture antibodies (Invitrogen AHC7109) and suspended in PBS.
- a microcentrifuge tube containing the mixture was shaken at 25° C. for 4 hours.
- the microspheres were washed once with 300 ⁇ L Tris-Starting Block (blocking buffer) and suspended in 300 ⁇ L blocking buffer.
- the suspension was shaken at 25° C. for 30 minutes and then washed once with 300 ⁇ L blocking buffer.
- the microsphere probes were suspended and stored in 100 ⁇ L blocking buffer at 4° C.
- a mixed solution of cells, anti-IL-10 conjugated microspheres (1 mg), and rat anti-human IL-10 FITC conjugated antibodies, at a concentration of 1 ⁇ g/mL (Invitrogen RHCIL1001) were ejected for encapsulation with a syringe. After encapsulation, the flow in the channels was stopped and the outlet of the device was blocked allowing previously encapsulated droplets to be incubated for 3 hours.
- Fluorescence images were captured on a Zeiss 200 Axiovert microscope using an AxioCAM MRm digital camera. FITC fluorescence (excitation 488 nm, emission 525 nm) was monitored to evaluate the microsphere assay ( FIG. 6B ).
- the method described combines the sensitivity of enhanced RCA detection with a reduction in reaction volumes, reagent, and sample consumption due to the microfluidic format.
- This system provides high-throughput, specific marker amplification of thousands of reactions per hour combined with real-time monitoring of individual reactions.
- various therapeutic strategies such as antibody- or gene-directed therapy, and small molecule approaches, exploiting the selective expression of targets on the surface of tumor-associated cell, could benefit from this sensitive and rapid protein surface detection method.
- the correlations between surface protein expressions data obtained from a tumor cell before treatment and after the responses of patients to various therapeutic regimens can be obtained on a single cell level.
- individual tumor cell analysis if applied for detection of CTCs, could provide important information, once a cell is recovered from a drop for future testing.
- FIGS. 5D , 6 A, and 6 B Single CD4+CD25+ regulatory T cells were encapsulated in distinct nL-sized microenvironment drops and IL-10 secretion was measured in the incubation channel.
- a detectable concentration of IL-10 secreted by an individual cell was reached in 2 to 3 hours in the restricted volume of droplet ( FIGS. 6A and 6B ).
- the droplets with a single cell that produced IL-10 were detected via a fluorescent signal accumulated on the surface of microspheres.
- FIGS. 6A and 6B depict aqueous droplets containing T cells, beads, and fluorescent secondary antibody after 3 hours incubation in the channel. The microspheres and cells can be seen in the bright field image ( FIG. 6A ).
- FIG. 6A depict aqueous droplets containing T cells, beads, and fluorescent secondary antibody after 3 hours incubation in the channel. The microspheres and cells can be seen in the bright field image ( FIG. 6A ).
- FIGS. 6A and 6B (right panels) present an encapsulated T cell which is not secreting IL-10 from the same batch experiment.
Abstract
This invention relates generally to a microfluidic device for encapsulation, incubation, and analysis of cell surface markers or secreted molecules from a single cell.
Description
- The invention relates to systems and methods for detecting molecules secreted from a single cell and rare cell surface markers, in particular, systems and methods using rolling circle amplification with microfluidic devices for encapsulation, incubation, and analysis of cell surface markers or secreted molecules from a single cell.
- The ability to gather statistical information over large populations of cells using flow cytometry of cells labeled with fluorescent probes has contributed tremendously to the diagnostics and study of cellular function. In a flow cytometer or a fluorescence-activated cell sorter (FACS), cells are interrogated by flowing them past a detector in a continuous stream of buffer and sorted by molecules either confined within the cells or bound to the cell surface, rather than by properties of the molecules the cells secrete (Koster et al., Lab on a Chip 8, 1110-1115 (2008); Herzenberg et al., Clin. Chem. 48, 1819-1827 (2002); Carroll and Al-Rubeai, Expert Opin. Biol. Ther. 4:1821-1829 (2004)). Low expression of a target molecule can lead to an insufficient or low-intensity detection signal. Further, to sort cells based on secreted molecules, additional tests are usually performed by enzyme-linked immunosorbent assay (ELISA) or comparable methods to verify secretion of a particular molecule of interest from a population of cells rather than from an individual cell. It is also challenging to determine time-dependent variability of secretion from single cells by current methods.
- The present invention is based, at least in part, on systems and methods for amplifying rare cell surface markers, in particular, systems and method using rolling circle amplification with microfluidic devices for encapsulation, incubation, and analysis of cell surface markers or secreted molecules from a single cell. The methods and systems described below can provide high efficiency techniques for specific detection and amplification of cell specific surface markers. The identification of cell surface antigens can be critical to the development of new diagnostic and therapeutic modalities for the management of diseases such as, for example, cancer.
- The systems and methods disclosed label cell surface specific markers using rolling circle amplification technique (RCA). RCA is a simple amplification method with high sensitivity and specificity owing to the DNA stringent strand matching requirement and its high signal amplification efficiency (see e.g., Konry et al., Analytical Chemistry 81(14), 5777-5782 (2009); Demidov, Expert Rev. Mol. Diagn., 2(6), 89-95, (2002); and Landegren et al., Comp. Funct. Genomics, 4, 525-530, (2003)). RCA technology detects and measures proteins as well as nucleic acids with unprecedented sensitivity and expanded multiplexing capabilities. A cell specific surface marker is a molecule usually found on the plasma membrane of a specific cell type or limited number of cell types. These markers can be extremely useful to distinguish diseased cells or tissues from those in normal state. The presented technique can be applied to identify, detect, and quantify specific types of cells in complex multi-cellular systems fixed on a glass slide, biochip platform or in flow cytometry analysis.
- In one aspect, methods of for detecting cell-surface expression or secretion of a protein or peptide by a single cell include: providing a sample comprising a population of cells and reagents sufficient for detection of a protein or peptide; dividing the sample into subsamples, such that each subsample contains at most one of the population of cells and each subsample is encompassed a hydrophobic fluid; maintaining the subsamples under conditions sufficient to allow detection of the protein or peptide; and detecting the protein or peptide; thereby detecting expression of the protein or peptide by a single cell. Embodiments can include one or more of the following features.
- In some embodiments, the protein or peptide is expressed on the surface of the cell or secreted from the cell.
- In some embodiments, the reagents comprises rolling circle amplification reagents, e.g., phi29 DNA polymerase, and circular DNA template.
- In some embodiments, the reagents comprise antibodies, e.g., antibodies that bind specifically to the protein or peptide.
- In some embodiments, the method further comprises sorting the cells based on expression of the protein or peptide. In some cases, wherein sorting the cells comprises using a Fluorescence Activated Cell Sorter (FACS).
- In some embodiments, dividing the sample into subsamples comprises combining fluids from multiple inlet channels. In some cases, combining the fluids from multiple inlet channels comprises combining aqueous sample fluid from a first inlet channel with a hydrophobic carrier fluid, e.g., oil, from at least one second inlet channel.
- In one aspect, systems for detecting expression of a specific protein or peptide by individual cells of a population of cells include: a fluid control device configured to divide a sample comprising the population of cells into subsamples, such that each subsample contains at most one of the population of cells and each subsample is encompassed a hydrophobic fluid; rolling circle amplification reagents for detection of the presence of the specific protein or peptide; and a device operable to detect the rolling circle amplification reagents in individual subsamples. Embodiments can include one or more of the following features.
- In some embodiments, systems also include a cell sorting mechanism operable to sort the subsamples based on measurement of an indicator parameter in each subsample. In some cases, the cell sorting mechanism comprises a fluorescence activated cell sorting mechanism.
- In one aspect, a kit includes: a fluid control device configured to divide a sample comprising the population of cells into subsamples, such that each subsample contains at most one of the population of cells and each subsample is encompassed a hydrophobic fluid; and rolling circle amplification reagents for detection of the presence of the specific protein or peptide. Embodiments can include one or more of the following features.
- In some embodiments, kits also include a device operable to detect the rolling circle amplification reagents in individual subsamples. In some cases, kits also include a cell sorting mechanism operable to sort the subsamples based on measurement of an indicator parameter in each subsample. For example, the cell sorting mechanism can include a fluorescence activated cell sorting mechanism.
- Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the specific systems and methods; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
- We have demonstrated real time RCA of cancer cell surface specific markers in a microfluidic format. A microfluidic system was used to encapsulate single cells in monodisperse pico-liter RCA reaction droplets. Inclusion of fluorescent probes in the RCA reaction mix permitted the amplification process to be monitored within individual droplets. The resulting fluorescent signal can be the basis for microfluidic cell sorting based on a cell surface marker.
- A PDMS microfluidic device was used for the production of monodisperse aqueous emulsion droplets with each droplet containing at most a single cell with a RCA reaction mix. This microfluidic system for RCA offers the advantage of a reduction of reaction volumes, and thereby decreases in reagent and sample consumption which can be critical when limited analyte material is available from clinical samples. Since RCA is an isothermal reaction there is no need for thermal cycling that require sophisticated and expensive instrumentation if compared to microfluidic systems for PCR (see e.g., Konry et al., Analytical Chemistry 81(14), 5777-5782 (2009); Demidov, Expert Rev. Mol. Diagn., 2(6), 89-95, (2002); and Landegren et al., Comp. Funct. Genomics, 4, 525-530, (2003)). Additionally, the new technique will potentially, due to the large multiplexing capacity of RCA, the methods described herein enable parallel detection of various markers thus providing a highly multiplex method by using different combinations of spectrally resolvable fluorophores. Such versatility is superior over PCR-based approaches, since multiplex PCR needs optimization for each primer pair used and still has problems with uniformity.
- Practical applications for the disclosed amplification labeling methods and systems for cell surface specific markers include, for example, in cancer cell diagnostics. The identification of cell surface antigens is critical to the development of new diagnostic and therapeutic modalities for the management of cancer. EpCAM, or ‘Epithelial Cell Adhesion Molecule’ is a pan-epithelial differentiation antigen that is expressed on almost all carcinomas. Therefore detection of EpCAM-expressing cells in the sample serves as the first screening test for cancer. In addition, this specific tumor cell marker is one criterion used in circulating tumor cell (CTC) identification. Usually, anti-EpCAM antibody is used to identify the CTCs. Cells that express this specific cancer marker can serve as molecular targets for sensitive and specific detection. However, tumor cells that express low levels of EpCAM may not detected directly by antiEpCAM antibodies due to low signal intensity. Therefore, the described systems and methods can provide the ability to detect differential expression of EpCAM on the cancer cell using RCA signal that can reduce the likelihood that any target cells are missed.
- The PDMS microfluidic devices can be used for production of monodisperse aqueous emulsion droplets of picoliter or nanoliter in size in a continuous oil phase to encapsulate each cell in their own microenvironment. In this hydrodynamic system, focusing, the size of a liquid jet can be considerably reduced to achieve faster mixing time. Since the volume of each drop is restricted, molecules secreted by an individual cell can rapidly attain detectable concentrations. Each droplet contains up to one individual cell encapsulated along with detection reagents, such as fluorescently labeled detection antibodies and conjugated microshperes for secreted analyte measurement (depending on the number of cells, some droplets may have no cells, but optimally no droplets will have more than one cell). In some embodiments, secreted analytes bind to microspheres previously conjugated with analyte-specific antibodies and this binding is detected in real time via detection of a fluorescent signal from labeled antibodies also present in the droplets. In the case of no analyte secretion from the cell, the fluorescence diffuses in the droplet and is not localized on the microshpere surface. Because the cells in the droplets remain viable after encapsulation, the cells can be captured based on signals detected, and cultured to produce clonal populations of cells, e.g., using known cell-sorting and culture methods. It is also possible that the same set of droplets could be used overtime to produce multiple copies of single cell droplets-array at different time points. This method has an advantage in the fabrication process and device handling, which avoids washing and surface modification steps as compared to previously published single cell secretion analysis. In addition, other methods for the analysis of individual cells in large numbers do not allow both high-throughput analysis of a secreted product and recovery of living cells for clonal expansion.
- Other features and advantages of the invention will be apparent from the following detailed description and figure, and from the claims.
-
FIG. 1 is a schematic illustration of an RCA assay for the detection of a target surface protein. -
FIG. 2 is a schematic illustration of a microfluidic cell sorting system for RCA in drops. -
FIGS. 3A to 3D are a series of microscope images of PC3 cells fixed on a glass slide. -
FIG. 4 is a schematic illustration of experimental setup. -
FIGS. 5A to 5C are a series of microscope images of microfluidic devices for encapsulation in created droplets. -
FIG. 5D is a photograph of an incubation and analysis channel. -
FIGS. 6A and 6B are a series of (A) bright field and (B) fluorescence microscope images of aqueous droplets containing T cells, beads, and fluorescent secondary antibody. - The systems and methods described herein are based, at least in part, on the discovery of methods for detecting molecules secreted by single cells and rare cell surface markers. In some embodiments, the methods use rolling circle amplification with microfluidic devices for encapsulation, incubation, and analysis of cell surface markers or secreted molecules from a single cell. Detection of cell surface specific markers in microfluidic format can be utilized in a number of applications, e.g., in cancer cell diagnostics.
- A cell surface marker is a molecule found on the external cell wall or plasma membrane of a specific cell type or a limited number of cell types (see e.g., Molday and Maher, Histochemical Journal 12:273-315 (1980); Hewett, International Journal of Biochemistry & Cell Biology 33:325-335 (2001); and Pembrey et al., Applied and Environmental Microbiology 65:2877-2894 (1999)). These markers are of importance in clinical studies and development of new diagnostic and therapeutic modalities for the management of human diseases such as cancer (see e.g., Molday and Maher, Histochemical Journal 12:273-315 (1980); Hewett, International Journal of Biochemistry & Cell Biology 33:325-335 (2001); and Pembrey et al., Applied and Environmental Microbiology 65:2877-2894 (1999)). Various therapeutic strategies could be employed to exploit the selective expression of targets on the surface of tumor-associated cell such as antibody- or gene-directed therapy, and small molecule approaches (Hewett, International Journal of Biochemistry & Cell Biology 33:325-335 (2001)). These therapeutic approaches depend on the identification of suitable selective targets on the associated tumor cell (Hewett, International Journal of Biochemistry & Cell Biology 33:325-335 (2001)). A significant challenge in diagnostic analysis of these targets via immunolabeling is insufficient or low-intensity detection signal due to low expression of the target. This leads to inefficient use of existing antibodies and a need for sensitive signal amplification technique. Therefore, the present methods, which can include use of the RCA technique can be used to enhance the intensity of the signal of the interrogated cell surface marker.
-
FIG. 1 schematically illustrates an exemplary RCA assay for the detection of analytes, e.g., a target surface protein. In this example, anti-EPCAM antibody binds to a target EpCAM protein and is in turn bound by secondary biotin-labeled antibodies (step A). An avidin bridge captures a biotinylated DNA probe (step B). Cyclic DNA is hybridized to the primer (step C), and the capture probe is extended by polymerase (step D). - It will be understood by skilled practitioners that any molecule that is secreted or found on the cell wall or plasma membrane of any cell, e.g., a marker can be detected. For example, cell surface markers that are expressed on a specific cell type or a limited number of cell types can be detected. The process will be described for use with cancer cells, although it may be adapted for use with other cells, e.g., stem cells and immune cells. Examples of cell surface markers include, but are not limited to, membrane proteins such as receptors, transporters, ion channels, proton pumps, and G protein-coupled receptors; extracellular matrix molecules such as adhesion molecules (e.g., integrins, cadherins, selectins, or NCAMS); See, e.g., U.S. Pat. No. 7,556,928, which is incorporated herein by reference in its entirety.
- Diagnostic markers for T-cells include the T-cell receptor (TCR) with its associated CD3 signaling complex as well as CD5 and the E-receptor (CD2). The presence of membrane immunoglobulin (mIg), which functions as antigen receptor, is diagnostic for B-cells. Complement receptors (CR) and Fc receptors (FcR) which can mediate opsonization, and MHC Class II molecules which are important in antigen presentation, are present on B-cells and macrophages, as well as dendritic cells. Two major classes of T-cells are distinguished by the presence of either CD4 (on TH and Treg) or CD8 (on TC). TH cells can be further subdivided into TH1 and TH2, which produce different cytokines and have distinct physiological roles.
- As used herein, secretion is the process of releasing a molecule from a cell, and occurs in prokaryotes and eukaryotes. For example, secretion is an important mechanism in bacterial functioning and operation in their natural surrounding environment for adaptation and survival. Eukaryotic cells have a highly evolved process of secretion, which may involve the classical endoplasmic reticulum (ER)-Golgi pathway. Many mammalian cell types have the ability to be secretory cells and thus have a well developed ER and Golgi apparatus to fulfill this function. Cells in humans that produce secretions include those in the gastrointestinal tract, which secretes digestive enzymes and gastric acid; the lung, which secretes surfactants; sebaceous glands, which secrete sebum to lubricate the skin and hair; the pancreas, which secretes insulin; and meibomian glands in the eyelid, which secrete sebum to lubricate and protect the eye. Further, cells of the immune system can secrete cytokines and proteins.
- Secretome analysis can be used e.g., to examine molecules secreted from specific cells, measure time-dependent variability of secretion, and identify unique types of cells that respond to activation with specific analyte secretion. The process will be described for use with IL-10, although it may be adapted for use with other secreted molecules, e.g., proteins, peptides, enzymes, cytokines, chemokines, hormones, toxins, and antimicrobial peptides.
- To demonstrate the ability of droplet based single cell secretion analysis, IL-10 secretion was measured from a CD4+CD25+ regulatory T cell clone. IL-10 is an anti-inflammatory cytokine with pleiotropic activities on B, T, and mast cells and is produced by a variety of cell types in response to activation (Pestka et al., Annu Rev Immunol. 22:929-79 (2004)). It has been reported that diminished IL-10 production is associated with autoimmunity (Astier and Hafler, J. Neuroimmunol. 191:70-8 (2007)). Thus, since IL-10 can exert its inhibitory activity through multiple effects on different cell types, it is important to understand how its secretion is regulated and to examine the unique cells that respond to IL-10. Understanding how IL-10 secretion is regulated in different cell types would be markedly enhanced by the ability to detect and re-isolate only those viable cells that are actively secreting IL-10 from the majority of cells in the population that are not producing IL-10. The technology described herein can be used to isolate IL-10 secreting cells by encapsulating cells, and later recovering the cells from the drops (e.g., using FACS).
- It will be understood by skilled practitioners that this method can also be applied to multitarget detection. Additional individually detectable microspheres that bind other targets can be incorporated in this type of secretion measurement. In this way, a single cell secretome can be achieved using multiple microspheres previously encoded with different capturing antibodies. The ability to use combinations of analytes for signal generation should enables simplification of sorting and detection analysis. For example, since monitoring of CD4+CD25+ regulatory T cells shows promise in cancer immunotherapy, the system can be applied to study new paradigms for designing cytokine antagonists and cell-cell regulation. The encapsulation of two different cells in the same droplet to study the direct interaction between them (with the secretion of a cytokine or the upregulation of a cell surface receptor as output), and screening of different blocking/agonistic antibodies to surface receptors could be some of the various further applications to this system.
-
FIG. 2 is a schematic illustration of a microfluidic cell sorting system for RCA in drops. The microfluidic device produces monodisperse aqueous emulsion droplets containing single cells and an RCA reaction mix. The droplets can then be incubated (e.g., stored in an incubation region of the microfluidic device). - The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
- EpCAM is a pan-epithelial differentiation antigen that is expressed on almost all carcinomas, therefore detection of EpCAM-expressing cells in a sample can serve as first screening test for cancer (Spizzo et al., Breast Cancer Research and Treatment 86:207-213 (2004)). In addition, this specific tumor cell marker is usually used to identify a circulating tumor cell (CTC) (Nagrath et al., Nature 450:1235-1238 (2007)). However tumor cells that express a low level of EpCAM may not be detected directly by anti-EpCAM antibodies due to low signal intensity (Deng et al., Breast Cancer Research 10:1-11 (2008)). Therefore the ability to detect differential expression of EpCAM on the cell using a RCA signal can ensure that no target cells are missed.
- An RCA signal can be confined locally if the amplification primer is immobilized onto a solid support (Konry et al., Analytical Chemistry 81: 5777-5782 (2009); Smolina et al., Applied and Environmental Microbiology 73:2324-2328 (2007)) and the resulting signal can be detected directly via fluorescent microscopy and/or digitally quantified with a GenePix® microarray scanner (Smolina et al., Applied and Environmental Microbiology 73:2324-2328 (2007)). Two sets of experiments were performed. Representative results obtained in these experiments are presented in
FIGS. 3A-3D . - Microscope images of PC3 cells fixed on a glass slide previously labeled with DAPI (blue) were taken. The PC3 cells were labeled directly with biotinylated anti-EpCAM antibodies and Cy3 fluorescent labeled streptavidin. The specificity of the system was also tested by applying the same conditions to lymphocytes. As lymphocyte cells do not express EpCAM, no fluorescent signal was detected using the direct detection method.
- In this experiment, PC3 cells were labeled using the RCA technique. In this approach, the cells were first labeled with biotinylated anti-EpCAM antibodies. Biotinylated primers were immobilized via a biotin-avidin bridge to the biotinylated anti-EpCAM antibodies. Next, circular template (padlock) was immobilized to the primers and isothermally amplified by phi29 DNA polymerase. As the amplification is isothermal, the RCA process preserves the integrity of antibody-antigen (EpCAM) complexes. The RCA product contains thousands of repeat sequences that contain fluorescently labeled nucleotides. RCA amplifies the detection signal and allows for the detection of PC3 cancer cells.
- Isothermal amplification using phi29 DNA polymerase was also performed in droplets. In order to evaluate the method for screening a single-cell, a drop-based PDMS microfluidic device was applied to encapsulate PC3 cells in distinct picoliter-sized drops of RCA reagents. A PDMS microfluidic system which generates monodisperse droplets in a microchannel through shearing flow at a T-junction or a flow-focusing zone has been previously described (Kiss et al., Anal. Chem. 80:8975-8981 (2008); Koster et al., Lab on a Chip, 8:1110-1115 (2008)). Other methods of generating droplets (e.g., separating the sample into subsamples) could also be used.
- The RCA reaction droplets were conveyed by the oil flow through channels in a microfluidic chip. Individual droplets were then focused in the array channel for amplification reaction of cell surface marker and optical interrogation (
FIGS. 3A to 3D ). An array like channel permits incubation for polymerization and measuring of fluorescence signal in real time from each individual cell, providing information on amplification efficiency within each droplet. The array channel herein permits simultaneous interrogation of multiple droplets/reactions/cells and it can be easily designed to hold thousands of droplets (Kiss et al., Anal. Chem. 80:8975-8981 (2008)). Comparing the fluorescent image of an encapsulated cell in an RCA reaction at the beginning of the incubation (seeFIG. 3C ) with the cell after 1.5 hours (seeFIG. 3D ), it is clear that the RCA was performed on a single PC3 cancer cell enclosed in a droplet. In this research setting, real-time RCA in pL-drops can provide quantitative measurements, if fluorescence was recorded using a custom optics system and software similar to one described by Kiss et al. (Anal. Chem. 80:8975-8981 (2008)). - The basic cell encapsulation device uses a flow focusing geometry to produce droplets (Brouzesa et al., Proc. Natl Acad. Sci. USA 106: 14195-14200 (2009); Edd et al., Lab Chip 9:1859-65 (2009); Koster et al., Lab Chip 8:1110-1115 (2008); Wan et al.)
FIG. 4 illustrates a PDMS droplet-based microfluidic device. Three inlet channels form a nozzle as their flows combine (seeFIGS. 5A and 5B ). The center stream contains beads, cell and secondary antibodies suspension while the side streams contain the oil phase. The size of the droplets controlled by matching the size of the nozzle orifice to the drop diameter and operating the device in the dripping regime. For drop formation, the flow rate ratio of water to oil was adjusted to the Qw/Qo=0.5. For single cell studies, all drops should optimally contain at most one cell, so that the majority of drops contain no cell at all since the encapsulation process follows Poisson statistics. Although the number of single-cell-bearing drops is rather low, for these experiments this is not severe, given the high production and screening rate that can be achieved with microfluidic devices. - Microfluidic flow chambers were fabricated by soft lithography. Negative photo resist SU-8 2025 or SU-8 2100 (MicroChem, Newton, Mass.) was deposited onto clean silicon wafers to a thickness of 50 lm, and patterned by exposure to UV light through a transparency photomask (CAD/Art Services, Bandon, Oreg.). The Sylgard 184 poly(dimethylsiloxane) (PDMS) (Dow Corning, Midland, Mich.) was mixed with crosslinker (ratio 10:1), poured onto the photoresist patterns, degassed thoroughly and cured for at least 1 hour at 65° C. The PDMS devices were peeled off the wafer and bonded to glass slides after oxygen-plasma activation of both surfaces. To improve the wetting of the channels with mineral oil, the microfluidic channels are treated prior to the experiments with Aquapel (PPG Industries, Pittsburgh, Pa.) by filling the channels with the solution as received and then flushing them with air. Polyethylene tubing with an inner diameter of 0.38 mm and an outer diameter of 1.09 mm (Becton Dickinson, Franklin Lakes, N.J.) connected the channels to the syringes. Syringes were used to load the fluids into the devices, while the flow rates were controlled by syringe pumps. Optimum devices for drop formation and cell encapsulation are 40 lm high with a 35 lm-wide nozzle. To vary the drop size, we also used a channel height of 25 lm and different nozzle widths. The channel for cell incubation are 100 lm high, the 1 width is 500 lm, and the length is 2.88 m. All inlet channels were equipped with patterned filters which prevent dust particles from clogging the channels downstream.
- As lymphocyte cells do not express EpCAM, no fluorescent signal was detected using the RCA methods.
- Whole mononuclear cells were isolated from human blood drawn from healthy control donors by Ficoll-Hypaque (Amersham Biosciences) gradient centrifugation, and total CD4 T cells were isolated by negative selection using a CD4+ T-cell isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) and stained for fluorescence-activated cell sorting (FACS) with antibodies against CD45RA (HI100), CD25 (M-A251), and HLA-DR (L-243). The specific DR-Treg (CD45RA−CD25highDR−) (Baecher-Allan et al., J. Immunol. 176:4622-31 (2006)), and memory T responder (CD45RA−CD25med) populations were sorted in a FACSAria™ cell sorter (BD Biosciences) at one cell per well in XVIVO-15 (Lonza) medium containing 5% human serum and stimulated with soluble anti-CD3 (clone Hit3a, BD Biosciences) and anti-CD28 (clone 28.2) (both at 1 μg/mL), irradiated APCs (105/well), and IL-2 (50 U/mL). Half of the medium was replaced with fresh medium containing IL-2 (50 U/mL) starting at day 10 and every 3 to 4 days thereafter. After 4 weeks of expansion, each clone was tested for FoxP3 expression and IL-10 production.
- SPHERO™ Avidin Coated Particles (0.7-0.9 lm) were conjugated with biotinylated IL-10 monoclonal capture antibodies (Invitrogen AHC7109) and suspended in PBS. A microcentrifuge tube containing the mixture was shaken at 25° C. for 4 hours. The microspheres were washed once with 300 μL Tris-Starting Block (blocking buffer) and suspended in 300 μL blocking buffer. The suspension was shaken at 25° C. for 30 minutes and then washed once with 300 μL blocking buffer. The microsphere probes were suspended and stored in 100 μL blocking buffer at 4° C.
- A mixed solution of cells, anti-IL-10 conjugated microspheres (1 mg), and rat anti-human IL-10 FITC conjugated antibodies, at a concentration of 1 μg/mL (Invitrogen RHCIL1001) were ejected for encapsulation with a syringe. After encapsulation, the flow in the channels was stopped and the outlet of the device was blocked allowing previously encapsulated droplets to be incubated for 3 hours.
- Fluorescence images were captured on a Zeiss 200 Axiovert microscope using an AxioCAM MRm digital camera. FITC fluorescence (excitation 488 nm, emission 525 nm) was monitored to evaluate the microsphere assay (
FIG. 6B ). - The method described combines the sensitivity of enhanced RCA detection with a reduction in reaction volumes, reagent, and sample consumption due to the microfluidic format. This system provides high-throughput, specific marker amplification of thousands of reactions per hour combined with real-time monitoring of individual reactions. In addition, various therapeutic strategies such as antibody- or gene-directed therapy, and small molecule approaches, exploiting the selective expression of targets on the surface of tumor-associated cell, could benefit from this sensitive and rapid protein surface detection method. The correlations between surface protein expressions data obtained from a tumor cell before treatment and after the responses of patients to various therapeutic regimens can be obtained on a single cell level. In addition, individual tumor cell analysis, if applied for detection of CTCs, could provide important information, once a cell is recovered from a drop for future testing.
- Single CD4+CD25+ regulatory T cells were encapsulated in distinct nL-sized microenvironment drops and IL-10 secretion was measured in the incubation channel (
FIGS. 5D , 6A, and 6B). A detectable concentration of IL-10 secreted by an individual cell was reached in 2 to 3 hours in the restricted volume of droplet (FIGS. 6A and 6B ). The droplets with a single cell that produced IL-10 were detected via a fluorescent signal accumulated on the surface of microspheres.FIGS. 6A and 6B depict aqueous droplets containing T cells, beads, and fluorescent secondary antibody after 3 hours incubation in the channel. The microspheres and cells can be seen in the bright field image (FIG. 6A ).FIG. 6B (left panel) shows the fluorescence image where secondary fluorescently labeled antibody has been localized on the beads, indicating the secretion of IL-10 from the cell and later binding to the microspheres.FIGS. 6A and 6B (right panels) present an encapsulated T cell which is not secreting IL-10 from the same batch experiment. - It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (15)
1. A method of detecting cell-surface expression or secretion of a protein or peptide by a single cell, the method comprising:
providing a sample comprising a population of cells and reagents sufficient for detection of a protein or peptide, wherein the reagents comprise rolling circle amplification reagents;
dividing the sample into subsamples, such that each subsample contains at most one of the population of cells and each subsample is encompassed a hydrophobic fluid;
maintaining the subsamples under conditions sufficient to allow detection of the protein or peptide; and
detecting the protein or peptide;
thereby detecting expression of the protein or peptide by a single cell.
2. The method of claim 1 , wherein the protein or peptide is expressed on the surface of the cell or secreted from the cell.
3. The method of claim 1 , wherein the rolling circle amplification reagents comprise phi29 DNA polymerase or circular DNA template or both.
4. The method of claim 1 , wherein the reagents comprise antibodies, e.g., antibodies that bind specifically to the protein or peptide.
5. The method of claim 1 , wherein the method further comprises sorting the cells based on expression of the protein or peptide.
6. The method of claim 5 , wherein sorting the cells comprises using a Fluorescence Activated Cell Sorter (FACS).
7. The method of claim 1 , wherein dividing the sample into subsamples comprises combining fluids from multiple inlet channels.
8. The method of claim 7 , wherein combining the fluids from multiple inlet channels comprises combining aqueous sample fluid from a first inlet channel with a hydrophobic carrier fluid, e.g., oil, from at least one second inlet channel.
9. A system for detecting expression of a specific protein or peptide by individual cells of a population of cells, the system comprising:
a fluid control device configured to divide a sample comprising the population of cells into subsamples, such that each subsample contains at most one of the population of cells and each subsample is encompassed a hydrophobic fluid;
rolling circle amplification reagents for detection of the presence of the specific protein or peptide; and
a device operable to detect the rolling circle amplification reagents in individual subsamples.
10. The system of claim 9 , further comprising a cell sorting mechanism operable to sort the subsamples based on measurement of an indicator parameter in each subsample.
11. The system of claim 10 , wherein the cell sorting mechanism comprises a fluorescence activated cell sorting mechanism.
12. A kit comprising:
a fluid control device configured to divide a sample comprising the population of cells into subsamples, such that each subsample contains at most one of the population of cells and each subsample is encompassed a hydrophobic fluid; and
rolling circle amplification reagents for detection of the presence of the specific protein or peptide.
13. The kit of claim 12 , further comprising a device operable to detect the rolling circle amplification reagents in individual subsamples.
14. The kit of claim 13 , further comprising a cell sorting mechanism operable to sort the subsamples based on measurement of an indicator parameter in each subsample.
15. The kit of claim 14 , wherein the cell sorting mechanism comprises a fluorescence activated cell sorting mechanism.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/583,478 US20130052648A1 (en) | 2010-03-12 | 2011-03-10 | Amplifying rare cell surface markers |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31366710P | 2010-03-12 | 2010-03-12 | |
PCT/US2011/027926 WO2011112827A2 (en) | 2010-03-12 | 2011-03-10 | Amplifying rare cell surface markers |
US13/583,478 US20130052648A1 (en) | 2010-03-12 | 2011-03-10 | Amplifying rare cell surface markers |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/027926 A-371-Of-International WO2011112827A2 (en) | 2010-03-12 | 2011-03-10 | Amplifying rare cell surface markers |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/982,458 Division US10054591B2 (en) | 2010-03-12 | 2015-12-29 | Amplifying rare cell surface markers |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130052648A1 true US20130052648A1 (en) | 2013-02-28 |
Family
ID=44564118
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/583,478 Abandoned US20130052648A1 (en) | 2010-03-12 | 2011-03-10 | Amplifying rare cell surface markers |
US14/982,458 Active 2031-05-07 US10054591B2 (en) | 2010-03-12 | 2015-12-29 | Amplifying rare cell surface markers |
US15/998,865 Abandoned US20190056405A1 (en) | 2010-03-12 | 2018-08-17 | Amplifying rare cell surface markers |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/982,458 Active 2031-05-07 US10054591B2 (en) | 2010-03-12 | 2015-12-29 | Amplifying rare cell surface markers |
US15/998,865 Abandoned US20190056405A1 (en) | 2010-03-12 | 2018-08-17 | Amplifying rare cell surface markers |
Country Status (2)
Country | Link |
---|---|
US (3) | US20130052648A1 (en) |
WO (1) | WO2011112827A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017502312A (en) * | 2013-12-19 | 2017-01-19 | ウニヴェルスィタ デッリ ストゥーディ ディ ウーディネ | Method for detecting circulating tumor cells (CTC) |
WO2017011819A1 (en) * | 2015-07-15 | 2017-01-19 | Northeastern University | Microdroplet based bioassay platform |
US20170199198A1 (en) * | 2016-01-12 | 2017-07-13 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
WO2017123537A1 (en) * | 2016-01-12 | 2017-07-20 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
CN112129736A (en) * | 2020-09-22 | 2020-12-25 | 四川大学华西医院 | Homogeneous phase visualization/fluorescence POCT detection method for mucin and circulating tumor cells |
US10928382B2 (en) * | 2014-06-26 | 2021-02-23 | Northeastern University | Microfluidic device and method for analysis of tumor cell microenvironments |
US20210146366A1 (en) * | 2018-04-18 | 2021-05-20 | Hifibio Sas | Microfluidic method for single cell analysis |
US11131673B2 (en) | 2017-04-27 | 2021-09-28 | Northeastern University | Live single-cell bioassay in microdroplets |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150346201A1 (en) * | 2013-01-07 | 2015-12-03 | Tali Korny | System and method for picoliter volume microfluidic diagnostics |
US10976232B2 (en) * | 2015-08-24 | 2021-04-13 | Gpb Scientific, Inc. | Methods and devices for multi-step cell purification and concentration |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080014589A1 (en) * | 2006-05-11 | 2008-01-17 | Link Darren R | Microfluidic devices and methods of use thereof |
US20100286290A1 (en) * | 2007-06-04 | 2010-11-11 | Jakob Schwalbe Lohmann | Enzyme activity assay using rolling circle amplification |
US20130209988A1 (en) * | 2009-11-23 | 2013-08-15 | The General Hospital Corporation | Microfluidic devices for the capture of biological sample components |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0114854D0 (en) * | 2001-06-18 | 2001-08-08 | Medical Res Council | Selective gene amplification |
TW200412373A (en) * | 2003-01-15 | 2004-07-16 | Univ Nat Taiwan | RCA combined nanoparticle-based optical detection technique for protein microarray |
US7759111B2 (en) * | 2004-08-27 | 2010-07-20 | The Regents Of The University Of California | Cell encapsulation microfluidic device |
-
2011
- 2011-03-10 WO PCT/US2011/027926 patent/WO2011112827A2/en active Application Filing
- 2011-03-10 US US13/583,478 patent/US20130052648A1/en not_active Abandoned
-
2015
- 2015-12-29 US US14/982,458 patent/US10054591B2/en active Active
-
2018
- 2018-08-17 US US15/998,865 patent/US20190056405A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080014589A1 (en) * | 2006-05-11 | 2008-01-17 | Link Darren R | Microfluidic devices and methods of use thereof |
US20100286290A1 (en) * | 2007-06-04 | 2010-11-11 | Jakob Schwalbe Lohmann | Enzyme activity assay using rolling circle amplification |
US20130209988A1 (en) * | 2009-11-23 | 2013-08-15 | The General Hospital Corporation | Microfluidic devices for the capture of biological sample components |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017502312A (en) * | 2013-12-19 | 2017-01-19 | ウニヴェルスィタ デッリ ストゥーディ ディ ウーディネ | Method for detecting circulating tumor cells (CTC) |
US10928382B2 (en) * | 2014-06-26 | 2021-02-23 | Northeastern University | Microfluidic device and method for analysis of tumor cell microenvironments |
WO2017011819A1 (en) * | 2015-07-15 | 2017-01-19 | Northeastern University | Microdroplet based bioassay platform |
US10802016B2 (en) | 2015-07-15 | 2020-10-13 | Northeastern University | Microdroplet based bioassay platform |
US10718763B2 (en) | 2015-07-15 | 2020-07-21 | Northeastern University | Microdroplet based bioassay platform |
EP3322981A4 (en) * | 2015-07-15 | 2019-03-20 | Northeastern University | Microdroplet based bioassay platform |
US10697972B2 (en) | 2016-01-12 | 2020-06-30 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
CN108780094A (en) * | 2016-01-12 | 2018-11-09 | 生物蛋白有限公司 | The diagnostic method of use condition active antibodies |
WO2017123537A1 (en) * | 2016-01-12 | 2017-07-20 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
US20170199198A1 (en) * | 2016-01-12 | 2017-07-13 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
US11131673B2 (en) | 2017-04-27 | 2021-09-28 | Northeastern University | Live single-cell bioassay in microdroplets |
US20210146366A1 (en) * | 2018-04-18 | 2021-05-20 | Hifibio Sas | Microfluidic method for single cell analysis |
US11904317B2 (en) * | 2018-04-18 | 2024-02-20 | Hifibio Sas | Microfluidic method for single cell analysis |
CN112129736A (en) * | 2020-09-22 | 2020-12-25 | 四川大学华西医院 | Homogeneous phase visualization/fluorescence POCT detection method for mucin and circulating tumor cells |
Also Published As
Publication number | Publication date |
---|---|
US10054591B2 (en) | 2018-08-21 |
WO2011112827A3 (en) | 2012-01-19 |
WO2011112827A2 (en) | 2011-09-15 |
US20190056405A1 (en) | 2019-02-21 |
US20160116479A1 (en) | 2016-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10054591B2 (en) | Amplifying rare cell surface markers | |
JP7374936B2 (en) | Microfluidic devices and their use in multicellular assays of secretions | |
EP3248018B1 (en) | Devices and systems for molecular barcoding of nucleic acid targets in single cells | |
Konry et al. | Droplet-based microfluidic platforms for single T cell secretion analysis of IL-10 cytokine | |
Lindström et al. | Overview of single-cell analyses: microdevices and applications | |
JP7416749B2 (en) | Apparatus and method for analysis of cell secretions | |
JP5241678B2 (en) | Microfluidic particle analysis system | |
RU2536291C2 (en) | Method to diagnose allergic reactions | |
US10613015B2 (en) | Methods for classification and sorting of cancer cells | |
EP2407242A1 (en) | Direct clone analysis and selection technology | |
US20220041967A1 (en) | Real-time monitoring of single cell or events | |
CN110760571A (en) | Digital quantitative multi-target joint biological detection | |
US20080020453A1 (en) | Analytical system based on porous material for highly parallel single cell detection | |
Chen et al. | Emerging microfluidic tools for functional cellular immunophenotyping: a new potential paradigm for immune status characterization | |
Van Lent et al. | Miniaturized single-cell technologies for monoclonal antibody discovery | |
Li et al. | Droplets microfluidics platform—A tool for single cell research | |
US10209241B2 (en) | High throughput sensitization detection devices and methods | |
CN117280210A (en) | Method for selecting cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YARMUSH, MARTIN L.;KONRY, TALI;SIGNING DATES FROM 20121025 TO 20121026;REEL/FRAME:031175/0433 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |